In contrast, a recent study revealed that combination of mitogen-activated protein kinase kinase (MEK) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors triggers senescence-associated secretory phenotype (SASP)–mediated increase in CD31+ cells and endothelial activation, promoting CD8+ T cell tumor infiltration. Here, PECAM1 is linked to neoplasm.